ANIX is trading 9.5% up today at $3.24 as investors refocus on progress within its ovarian cancer CAR-T program.
- The company recently treated the first patient in the highest-dose fifth cohort of its Phase 1 trial with no dose-limiting toxicities reported.
- Multiple patients are showing long survival, drawing renewed market attention to the trial's success despite a recent intraday sell the news swing.